ArticleCancer science2018

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data.

Takahisa Kawamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.